An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration.


Journal

The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309

Informations de publication

Date de publication:
12 2019
Historique:
received: 08 04 2019
revised: 11 07 2019
accepted: 18 07 2019
pubmed: 8 10 2019
medline: 13 6 2020
entrez: 8 10 2019
Statut: ppublish

Résumé

Approximately 20% of traumatic cervical spinal cord injuries result in tetraplegia. Neuroprosthetics are being developed to manage this condition and thus improve the lives of patients. We aimed to test the feasibility of a semi-invasive technique that uses brain signals to drive an exoskeleton. We recruited two participants at Clinatec research centre, associated with Grenoble University Hospital, Grenoble, France, into our ongoing clinical trial. Inclusion criteria were age 18-45 years, stability of neurological deficits, a need for additional mobility expressed by the patient, ambulatory or hospitalised monitoring, registration in the French social security system, and signed informed consent. The exclusion criteria were previous brain surgery, anticoagulant treatments, neuropsychological sequelae, depression, substance dependence or misuse, and contraindications to magnetoencephalography (MEG), EEG, or MRI. One participant was excluded because of a technical problem with the implants. The remaining participant was a 28-year-old man, who had tetraplegia following a C4-C5 spinal cord injury. Two bilateral wireless epidural recorders, each with 64 electrodes, were implanted over the upper limb sensorimotor areas of the brain. Epidural electrocorticographic (ECoG) signals were processed online by an adaptive decoding algorithm to send commands to effectors (virtual avatar or exoskeleton). Throughout the 24 months of the study, the patient did various mental tasks to progressively increase the number of degrees of freedom. Between June 12, 2017, and July 21, 2019, the patient cortically controlled a programme that simulated walking and made bimanual, multi-joint, upper-limb movements with eight degrees of freedom during various reach-and-touch tasks and wrist rotations, using a virtual avatar at home (64·0% [SD 5·1] success) or an exoskeleton in the laboratory (70·9% [11·6] success). Compared with microelectrodes, epidural ECoG is semi-invasive and has similar efficiency. The decoding models were reusable for up to approximately 7 weeks without recalibration. These results showed long-term (24-month) activation of a four-limb neuroprosthetic exoskeleton by a complete brain-machine interface system using continuous, online epidural ECoG to decode brain activity in a tetraplegic patient. Up to eight degrees of freedom could be simultaneously controlled using a unique model, which was reusable without recalibration for up to about 7 weeks. French Atomic Energy Commission, French Ministry of Health, Edmond J Safra Philanthropic Foundation, Fondation Motrice, Fondation Nanosciences, Institut Carnot, Fonds de Dotation Clinatec.

Sections du résumé

BACKGROUND
Approximately 20% of traumatic cervical spinal cord injuries result in tetraplegia. Neuroprosthetics are being developed to manage this condition and thus improve the lives of patients. We aimed to test the feasibility of a semi-invasive technique that uses brain signals to drive an exoskeleton.
METHODS
We recruited two participants at Clinatec research centre, associated with Grenoble University Hospital, Grenoble, France, into our ongoing clinical trial. Inclusion criteria were age 18-45 years, stability of neurological deficits, a need for additional mobility expressed by the patient, ambulatory or hospitalised monitoring, registration in the French social security system, and signed informed consent. The exclusion criteria were previous brain surgery, anticoagulant treatments, neuropsychological sequelae, depression, substance dependence or misuse, and contraindications to magnetoencephalography (MEG), EEG, or MRI. One participant was excluded because of a technical problem with the implants. The remaining participant was a 28-year-old man, who had tetraplegia following a C4-C5 spinal cord injury. Two bilateral wireless epidural recorders, each with 64 electrodes, were implanted over the upper limb sensorimotor areas of the brain. Epidural electrocorticographic (ECoG) signals were processed online by an adaptive decoding algorithm to send commands to effectors (virtual avatar or exoskeleton). Throughout the 24 months of the study, the patient did various mental tasks to progressively increase the number of degrees of freedom.
FINDINGS
Between June 12, 2017, and July 21, 2019, the patient cortically controlled a programme that simulated walking and made bimanual, multi-joint, upper-limb movements with eight degrees of freedom during various reach-and-touch tasks and wrist rotations, using a virtual avatar at home (64·0% [SD 5·1] success) or an exoskeleton in the laboratory (70·9% [11·6] success). Compared with microelectrodes, epidural ECoG is semi-invasive and has similar efficiency. The decoding models were reusable for up to approximately 7 weeks without recalibration.
INTERPRETATION
These results showed long-term (24-month) activation of a four-limb neuroprosthetic exoskeleton by a complete brain-machine interface system using continuous, online epidural ECoG to decode brain activity in a tetraplegic patient. Up to eight degrees of freedom could be simultaneously controlled using a unique model, which was reusable without recalibration for up to about 7 weeks.
FUNDING
French Atomic Energy Commission, French Ministry of Health, Edmond J Safra Philanthropic Foundation, Fondation Motrice, Fondation Nanosciences, Institut Carnot, Fonds de Dotation Clinatec.

Identifiants

pubmed: 31587955
pii: S1474-4422(19)30321-7
doi: 10.1016/S1474-4422(19)30321-7
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1112-1122

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Alim Louis Benabid (AL)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CHU Grenoble Alpes, Grenoble, France. Electronic address: alimlouis@sfr.fr.

Thomas Costecalde (T)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Andrey Eliseyev (A)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Guillaume Charvet (G)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Alexandre Verney (A)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CEA, LIST, DIASI, SRI, Gif-sur-Yvette, France.

Serpil Karakas (S)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Michael Foerster (M)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Aurélien Lambert (A)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Boris Morinière (B)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CEA, LIST, DIASI, SRI, Gif-sur-Yvette, France.

Neil Abroug (N)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CEA, LIST, DIASI, SRI, Gif-sur-Yvette, France.

Marie-Caroline Schaeffer (MC)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Alexandre Moly (A)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Fabien Sauter-Starace (F)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

David Ratel (D)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Cecile Moro (C)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Napoleon Torres-Martinez (N)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Lilia Langar (L)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CHU Grenoble Alpes, Grenoble, France.

Manuela Oddoux (M)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CHU Grenoble Alpes, Grenoble, France.

Mircea Polosan (M)

CHU Grenoble Alpes, Grenoble, France.

Stephane Pezzani (S)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CHU Grenoble Alpes, Grenoble, France.

Vincent Auboiroux (V)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Tetiana Aksenova (T)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Corinne Mestais (C)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France.

Stephan Chabardes (S)

CEA, LETI, Clinatec, University of Grenoble, Grenoble, France; CHU Grenoble Alpes, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH